Definition of the cellular interactome of the highly pathogenic avian influenza H5N1 virus: identification of human cellular regulators of viral entry, assembly, and egress. by Kien, F et al.
10 Hong Kong Med J  ⎥  Volume 22 Number 3 (Supplement 4)  ⎥  June 2016  ⎥  www.hkmj.org Hong Kong Med J  ⎥  Volume 22 Number 3 (Supplement 4)  ⎥  June 2016  ⎥  www.hkmj.org
K e y  M e s s a g e s 
1. Novel H5N1-human host protein-protein 
interactions were identified using a genome-wide 
yeast two-hybrid screen.
2. Annexin A6 interacts with the cytoplasmic tail of 
influenza A M2 protein.
3. Annexin A6 negatively regulates influenza A 
infection.
4. Annexin A6 impairs influenza A virus budding 
and release.
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Introduction
Influenza A virus causes acute infection of the 
respiratory tract in humans. H1N1 and H3N2 viral 
strains are responsible for seasonal epidemics. 
Symptoms include fever, headache, chills, myalgia, 
dry cough and sore throat. Influenza is usually a 
self-limiting disease with recovery within a week 
in healthy individuals. Nonetheless, risk of serious 
illness affects young children, the elderly and 
patients with underlying health conditions. Due 
to antigenic variation of the virus, vaccination 
only enables incomplete protection. Circulation 
of influenza viruses in the animal reservoir causes 
additional threat. Because of rapid adaptation of 
viruses to environmental pressures, drugs directed 
against viral components are likely to induce 
selection of drug-resistant strains.1 Our strategy is 
to characterise cellular pathways used by viruses in 
the human host and identify potential novel cellular 
targets for drug development. 
 The spread of H5N1 avian influenza in South 
East Asia in the mid 2000s, its extreme virulence 
in poultry and the threat of a deadly pandemic in 
humans prompted us to work on this virus. We 
used a yeast-two hybrid approach to screen the 
entire human genome for factors that interact with 
H5N1 viral structural proteins. We had previously 
successfully used this technology for virus-host 
interaction studies on the severe acute respiratory 
syndrome coronavirus.2,3 Six highly relevant 
Hong Kong Med J 2016;22(Suppl 4):S10-2
RFCID project number: 09080892
1,2,3 F Kien, 1,4 HL Ma, 1,5 R Bruzzone, 3 LLM Poon, 1,6 B Nal
1  HKU-Pasteur Research Pole, Hong Kong
2 Ksilink, French-German Advanced Translational Centre, Strasbourg, 
France
3 Centre of Influenza Research, School of Public Health, LKS Faculty of 
Medicine, The University of Hong Kong, Hong Kong SAR, China
4 Emory University Vaccine Research Center, Atlanta, Georgia, USA
5 Department of Cell Biology and Infection, Institut Pasteur, Paris, France
6 Brunel University London, Division of Biosciences, College of Health and 
Life Sciences, Uxbridge, United Kingdom
* Principal applicant: francois.kien@ksilink.com
† Corresponding author: beatrice.nal-rogier@brunel.ac.uk
interactions were identified for H5, M1, and M2. 
Pilot biochemical confirmation of interactions and 
gene silencing studies prompted us to primarily 
focus on human annexin A6 (AnxA6). The yeast-
two hybrid assay had revealed that AnxA6 binds the 
cytosolic tail of the viral M2 proton channel.
 M2 is an essential protein for the virus. It 
has a proton channel activity with key roles during 
virus entry and uncoating, transport of viral 
haemagglutinin to the cell surface and assembly, 
budding and release of progeny virions at the surface 
of infected cells.4 There, M2 is known to accumulate 
at the edges of cholesterol-enriched viral budding 
platforms and induce a negative membrane curvature 
at the neck of the bud, responsible for scission and 
release of viral particles.5
 AnxA6 belongs to the annexin family of human 
proteins. It plays important roles in membrane 
trafficking and cell signalling in mammalian 
cells. Its overexpression has been shown to cause 
accumulation of cholesterol in late endosomes and 
alter transport and recycling of cellular cargos.6
 In this study we confirmed interaction between 
influenza M2 and human AnxA6 and demonstrated 
that AnxA6 restricts release of progeny viruses from 
infected cells.
Methods
This study was conducted from October 2009 
to September 2011. To confirm the interaction 
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identified in yeast (Hybrigenics, Paris, France), both 
biochemical and microscopy assays were performed. 
To determine whether AnxA6 is essential for 
infection both AnxA6 depletion and AxnA6 
overexpression studies were analysed. Steps of virus 
life cycle regulated by AnxA6 were identified using a 
comprehensive and systematic dissection of the viral 
life cycle. Impact of AnxA6 expression modulation 
on infection was studied using the previously 
mentioned AnxA6 depletion and overexpression 
protocols together with virus life cycle step-specific 
assays such as transmission electron microscopy to 
study virus budding and morphology.
Results
We hypothesised that cellular factors interacting 
with influenza M2 54-residue cytoplasmic tail (CT) 
could either help or restrict processes involving 
M2. We identified a novel interaction between the 
M2 CT of a highly pathogenic avian influenza strain 
(H5N1) and human AnxA6 in yeast. This interaction 
was confirmed in vitro using GST pull-down assay 
with M2 CT of the laboratory adapted influenza 
strain A/WSN/33 (H1N1). We found that a GST-M2 
CT fusion protein interacts and pulls down AnxA6 
from total human cell lysate, demonstrating that 
this interaction is not an artefact observed in the 
yeast system and the interaction is shared among 
different viral subtypes. Physical interaction was 
further confirmed in human virus-infected cells 
using a reciprocal co-immunoprecipitation assay 
of recombinant myc-AnxA6 and viral M2 protein. 
Co-localisation studies using confocal fluorescent 
microscopy showed a partial co-localisation of 
viral M2 and recombinant GFP-AnxA6 in distinct 
puncta-like areas at or close to the plasma membrane 
of virus-infected human cells, suggesting that this 
interaction occurs close to the virus assembly and 
budding site. 
 To define the role and impact of M2-AnxA6 
interaction on the viral replication cycle, we used 
two complementary approaches and studied the 
effect of AnxA6 depletion or overexpression on 
the production of viral particles. AnxA6 depletion 
significantly increased virus production, while 
overexpression reduced the titre of virus progeny, 
suggesting a negative regulatory role for AnxA6 
during influenza A virus infection. This was observed 
with different virus strains and subtypes of human 
seasonal influenza viruses, A/WSN/33 (H1N1), 
A/HK/1/68 (H3N2), and A/HK/54/98 (H1N1), 
suggesting a common hijacked cellular pathway by 
influenza A viruses. 
 Using AnxA6 depletion or overexpression 
protocols combined with virus life cycle step-
specific assay, we showed that AnxA6 does not affect 
virus binding and entry, vRNA replication and viral 
mRNA transcription, viral polymerase complex 
activity or NP nuclear export. On the contrary, we 
demonstrated that AnxA6 negatively modulates 
influenza virus infection by affecting virus budding 
as indicated by a drop in progeny virus PFU titre in 
supernatants and an increased number of virions at 
the cell surface of cells overexpressing AnxA6, which 
exhibit an elongated rather than spherical shape. 
This was observed by a semi-quantitative analysis 
of virus budding and morphology by transmission 
electron microscopy. These results demonstrate that 
AnxA6 overexpression results in defects in virus 
budding and release of infectious viral particles.
Discussion
This work identified AnxA6 as a novel cellular 
regulator that impairs virus budding and release 
stages of the lifecycle of influenza A virus. We 
proposed that AnxA6 acts as a restricting factor of 
influenza virus budding either by interacting with 
M2, which is able to mediate membrane scission,5 or 
by modulating cellular components such as cortical 
actin and cholesterol7 involved in viral budding, or 
both. Use of a recombinant mutant WSN influenza 
virus lacking M2 suggested that regulation of 
influenza virus production by AnxA6 is dependent 
on M2 and its interaction with AnxA6; this work has 
been published.8 Since then inhibition of influenza 
A virus production by AnxA6 has been further 
confirmed, and this effect linked to deregulation of 
cholesterol transport by AnxA6.9
 Our study has enhanced the understanding 
of cellular factors requirements for influenza A 
virus assembly and budding and underscores 
the unique budding strategy implemented by 
this virus. Nevertheless, the detailed molecular 
mechanism underlying this AnxA6-mediated 
negative modulation of influenza virus budding 
awaits further investigation. It will be important to 
determine the functional correlation between M2-
AnxA6 interaction and the defective viral budding 
phenotype. This research will help to delineate 
new strategies for the rational design of antiviral 
molecules.
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